Do you incorporate immunotherapy in your multi-modality treatment after chemoradiation for patients with potentially resectable stage III superior sulcus NSCLC?

No. Durvalumab therapy in NSCLC is currently limited to patients with unresectable disease. PACIFIC clearly demonstrated an enduring survival benefit of consolidative Durvalumab therapy after combined chemo-radiation therapy in patients who did not undergo surgical resection. The NeoCOAST trial is c...

Based on the data and NCCN guidelines, yes for immunotherapy (atezolizumab) and no for durvalumab.

For superior sulcus tumors with T3 invasion and N0-1 nodal involvement, preoperative concurrent chemoradiation followed by surgery plus adjuvant chemotherapy and atezolizumab or osimertinib (depending ...